Comparative Pharmacology
Head-to-head clinical analysis: EPROSARTAN MESYLATE versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPROSARTAN MESYLATE versus FILSPARI.
EPROSARTAN MESYLATE vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eprosartan mesylate is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Oral, 600 mg once daily. May increase to 800 mg once daily if inadequate response.
200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is about 5–9 hours. Clinical context: supports once-daily dosing for hypertension.
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Primarily biliary/fecal (≈90% as unchanged drug); renal elimination accounts for ≈7% (mostly unchanged).
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category D/X
Category C
ARB
Endothelin Receptor Antagonist / ARB